NEW YORK (GenomeWeb) – NIPD Genetics said today that it has signed a partnership agreement with Medicover covering NIPD Genetics' noninvasive prenatal tests, as well as the development of new tests.
The deal includes cooperation, investment, and a facility agreement that provides substantial capital to grow sales and research and development, according to Cyprus-based NIPD Genetics.
As part of the collaboration, the two companies will bring NIPD Genetics' Veracity and Veragene noninvasive prenatal tests to Medicover's network and other new markets. In addition, the firms will design and develop new genetic tests in the prenatal, postnatal, neonatal, oncology, and other spaces.
"This partnership offers us the ability to develop further our R&D plan and commercialize our products," NIPD Genetics CEO and Founder Philippos Patsalis said in a statement. "We look forward to growing together by leveraging the complementarities of both companies in providing advanced genetic testing services."
Warsaw, Poland-based Medicover previously announced in October that it reached a deal to purchase Invitro's Ukranian laboratory operations for €6 million ($6.9 million).